How to Prepare Clinical Evaluation Documentation for Overseas Medical Device Registration

Published: 9 July 2026, 13:20  |  Last updated: 9 July 2026, 13:20

Key Takeaways

Preparing clinical evaluation documentation for overseas medical device registration is a decisive step that directly determines whether a product can be approved in the target market. Manufacturers should determine the clinical evaluation route on the basis of the target country's regulatory requirements (for example, EU MDR, U.S. FDA, China NMPA, GHWP member states) and the device's risk class (Class IIa, Class IIb, Class III, etc.). High-risk devices generally require clinical investigation data, whereas lower-risk devices may satisfy clinical evaluation through literature review, equivalence justification or performance comparison.

During preparation, manufacturers should review existing technical files held under NMPA, CE, FDA or ISO 13485 systems, assess their reusability, and address localisation requirements such as translation and adaptation to local regulatory formats. Common risks include: misclassifying the product, selecting the wrong clinical evaluation route, insufficient clinical evidence, failure to consider post-market clinical follow-up (PMCF) requirements, and unclear responsibilities of the local representative. Manufacturers should first complete product classification, then develop a clinical evaluation plan, collect all necessary clinical data, write the clinical evaluation report, and ensure the report complies with the format recommended by the target country. In parallel, a collaboration mechanism with the local agent or authorised representative should be established, clarifying responsibilities for changes and renewals. For multi-country registration, core clinical evidence should be reused as a priority, supplemented according to country-specific requirements (for example, China's requirement to conduct clinical trials within its territory). During the post-market maintenance phase, clinical data should be collected continuously and the clinical evaluation report updated to withstand periodic regulatory review.

Compiled from AIMEILI's regulatory practice resources, the medical device international registration knowledge base and publicly available regulatory information. Specific projects should be based on the latest requirements of the target country's regulatory authority and the underlying product documentation.

Scope and Core Questions

This guide is intended for manufacturers planning to place medical devices on overseas markets, CROs, overseas business leads and regulatory affairs professionals. The core question is: how should clinical evaluation documentation be prepared so that it meets the requirements of the target country's regulatory framework?

Clinical evaluation is the key evidence demonstrating a device's safety and performance. Within the EU MDR, U.S. FDA, China NMPA, Japan PMDA, Southeast Asian (such as Thailand, Indonesia, Malaysia), Middle Eastern (Saudi Arabia, UAE) and Latin American (Brazil, Mexico) regulatory systems, the adequacy of clinical evaluation documentation directly affects both the speed and the success rate of registration approval.

Manufacturers must first recognise that clinical evaluation does not refer only to a clinical investigation report. It comprises a systematic assessment of the device's clinical data and may involve literature search, equivalence justification, clinical investigation data and post-market clinical follow-up. Definitions and acceptance levels of "clinical evaluation" differ between countries. For example, the EU MDR requires manufacturers to perform clinical evaluation continuously and to update the clinical evaluation report periodically; the U.S. FDA scrutinises clinical trial design strictly through the IDE and PMA processes; and China's NMPA requires in-territory clinical trials for certain high-risk devices, or accepts overseas clinical trial data that comply with the Good Clinical Practice for Medical Device Clinical Trials.

Regulatory Decision Logic

Step 1: Determine whether the product falls within the target country's medical device regulatory scope

In the EU, for example, certain aesthetic products may qualify as medical devices (such as tattoo machines) but must meet the MDR definition; in Saudi Arabia, it must be confirmed whether the product appears in the SFDA device list.

Step 2: Determine the risk class

Classification is based on intended use, degree of invasiveness and mechanism of action. The EU uses Class I (non-measuring, non-sterile, non-reusable), Class IIa, Class IIb and Class III; the United States uses Class I, II and III; China uses Class I, II and III. Different risk classes correspond to different clinical evaluation requirements.

Step 3: Assess the reusability of existing registration documentation

If a device has already been approved by China's NMPA or holds CE (MDD/MDR) or FDA (510(k) or PMA) certification, its clinical data can often serve as a foundation, but its compliance with the target country's data acceptance criteria must be verified. Brazil's ANVISA, for example, may require local clinical data or data from a specific ethnic population; Japan's PMDA typically requires local clinical trials or bridging studies.

Step 4: Confirm whether a local agent or authorised representative is required

The vast majority of countries require overseas manufacturers to appoint a local agent responsible for communication with the regulator and post-market surveillance. The agent's role is critical in the submission of clinical evaluation documentation and in subsequent changes.

Step 5: Plan the post-market clinical follow-up (PMCF) programme

The EU MDR explicitly requires manufacturers to collect data under a PMCF plan and to update the clinical evaluation report at least annually; the U.S. FDA requires post-market studies for high-risk devices.

Documentation and Evidence

Clinical evaluation documentation typically includes: a clinical evaluation plan (CEP); a clinical evaluation report (CER); a literature search protocol and report; an equivalence justification report (where applicable); a clinical investigation protocol and report (where applicable); a PMCF plan and report (where applicable); a risk analysis versus clinical data cross-reference table; and documents specific to the target country (such as China's clinical trial filing certificate and ethics committee approval).

For lower-risk devices (Class I or Class IIa), a literature review and performance data may suffice, with no clinical investigation required. Under the EU MDD, for example, Class I non-measuring, non-sterile devices could be exempt from clinical evaluation. The MDR has tightened this: almost all devices now require at least a literature review. For Class IIb and above, implantable devices or long-term use devices, clinical investigation data or a robust equivalence justification is generally required.

Equivalence justification is the most frequently used route, but it requires demonstrating identical clinical, technical and biological characteristics with an already marketed device. Manufacturers must collect detailed technical parameters, clinical data and market history of the equivalent device, and write an equivalence justification report. Among GHWP (Global Harmonization Working Party) member states — including China, Japan, Korea and the ASEAN countries — the acceptance criteria for equivalence justification may differ. China's NMPA, for example, requires the equivalent device to hold registration in China and does not accept direct citation of overseas equivalent devices.

Clinical investigation documentation must comply with international standards such as ISO 14155 and ICH GCP, and must take ethnic differences into account. For multi-country registration, global multicentre trial data may be used, provided that each sub-centre's data complies with local regulatory requirements. When preparing documentation, all clinical evidence should be consolidated and written according to the CER format recommended by the target country (for example, the EU MEDDEV 2.7/1 Rev.4 template), with complete references and full-text literature appended.

Common Errors

• Incorrect risk classification: classifying a Class IIb device as Class IIa, resulting in insufficient clinical evaluation documentation and a regulatory request for a full clinical investigation.
• Wrong clinical evaluation route: overlooking the MDR's PMCF requirement for all devices and failing to submit a PMCF plan at registration, which suspends the review.
• Insufficient equivalence justification: citing only a small number of publications or relying on a non-comparable equivalent device, without a full technical, biological and clinical demonstration, leading to rejection.
• Non-compliant literature search protocol: failing to use systematic review methodology, choosing inappropriate search terms or databases, or not documenting the search process, so that the clinical evaluation report is not accepted.
• Ignoring localisation requirements: translating an NMPA clinical investigation report directly into English for submission to the FDA without accounting for the FDA's specific requirements on data format and statistical analysis.
• No local agent or authorised representative: in some countries (such as Brazil and Saudi Arabia) an overseas manufacturer cannot submit directly and must appoint a local agent; otherwise clinical evaluation documentation will not be accepted.
• Missing post-market plan: failure to provide a PMCF plan or post-market study commitment, preventing conditional approval of high-risk devices.
• Failure to update the CER periodically: not updating the clinical evaluation report annually or upon significant changes after registration, which is identified during renewal or an unannounced inspection.

Manufacturer Preparation Checklist

• Confirm the medical device classification in the target country and obtain the official basis for classification.
• Develop a clinical evaluation plan (CEP) specifying data types, sources and analytical methods.
• Organise existing registration documentation — NMPA registration certificate, CE certificate, FDA 510(k)/PMA, ISO 13485 certificate, MDSAP certificate — and assess its reusability.
• Conduct a literature search: prepare a search protocol, use at least two independent databases (such as PubMed and Embase) and retain the search strategy and results.
• Where equivalence justification is required: identify the equivalent device, collect its technical, biological and clinical data, and write the equivalence justification report.
• Confirm whether a clinical investigation is required: communicate with the regulator (for example, through a pre-submission meeting) or consult the local agent.
• Write the clinical evaluation report (CER) following the format recommended by the target country, with annexes including full-text literature, the equivalence justification report and the clinical investigation report.
• Prepare a post-market clinical follow-up plan (PMCF Plan) specifying methods, frequency and responsible persons.
• Appoint a local authorised representative or agent and conclude an agreement defining its responsibilities for updating clinical evaluation documentation.
• Carry out an internal or third-party review before submission to ensure completeness, logical consistency and translation accuracy.
• Establish an SOP for updating clinical evaluation documentation, covering change control (such as design changes or new clinical data) and periodic update requirements.

AIMEILI Perspective

The most common misjudgements manufacturers make when preparing overseas clinical evaluation documentation concern product classification and the choice of clinical evaluation route. We frequently observe companies classifying products as low risk based on experience while overlooking the latest regulatory changes in the target country. The MDR's definition of an implant, for example, is broader than the MDD's, and some devices that were Class IIa under the MDD may be upgraded to Class IIb under the MDR. Classification consultation should therefore be carried out at the very beginning of a project, and where necessary confirmed through the regulator's classification tools or official Q&A.

We recommend that manufacturers prepare a clinical evidence gap analysis at project outset, comparing existing data against target-country requirements item by item to identify what must still be generated. This avoids discovering documentation shortfalls late in the registration process, which causes delay and additional cost. Core reusable documents include ISO 10993 biological evaluation reports, electrical safety test reports, risk management reports (ISO 14971) and clinical data generated in-country or under CE/FDA pathways. Localisation conversion must nonetheless be observed: the EU CER must be written in English and comply with the MEDDEV format; China's NMPA clinical evaluation report must include a Chinese abstract and Chinese-language references; Brazil's ANVISA requires a Portuguese translation with notarisation.

Control over the local agent is also very important. Many manufacturers find after registration that a change of agent or a break in communication prevents timely updating of clinical evaluation documentation, affecting renewals and changes. The agreement should therefore clearly set out the agent's responsibilities for document custody, submission and updating, and the manufacturer should also retain a complete set of original files. For multi-country registration we strongly recommend a "core clinical evaluation report plus country annexes" model: prepare one globally applicable core CER and then add a country-specific annex covering local applicability, ethnic difference analysis and additional data. This substantially reduces duplication and deficiency risk and improves multi-country registration efficiency.

Finally, post-market maintenance must not be neglected. Even after approval, regulators may still request PMCF data. Manufacturers should establish a continuous clinical data collection mechanism — such as complaint analysis, literature monitoring and clinical registry studies — and update the CER periodically. This not only satisfies compliance requirements but also generates clinical evidence for future product upgrades and new market registrations.

Frequently Asked Questions

Q1: My device is already registered in China (NMPA) with clinical trial data. Can that data be reused in full for EU registration?

Not necessarily. If the Chinese clinical trial complied with ISO 14155 and ICH GCP and its design, population and endpoints are consistent with EU MDR requirements, the data can be accepted. However, the EU MDR sets more specific requirements on clinical follow-up duration, patient numbers and statistical analysis, which may necessitate additional analyses or supplementary data. In addition, all materials must be translated into English and the CER written in accordance with MEDDEV 2.7/1 Rev.4. If the original trial was conducted mainly in a Chinese population, an ethnic difference analysis must be provided to demonstrate that the data can be extrapolated to the European population.

Q2: My product is a low-risk Class I device (non-measuring, non-sterile, non-reusable). Is clinical evaluation completely unnecessary?

Under the EU MDD, Class I non-measuring, non-sterile devices could be exempt from clinical evaluation. Under the MDR, however, all Class I devices require clinical evaluation, although a full clinical investigation may not be necessary and a literature review may suffice. A Class I general surgical instrument, for example, can demonstrate safety through literature. Other jurisdictions follow a similar pattern: the U.S. FDA generally exempts Class I devices from 510(k) but applies general controls; China's NMPA requires a risk analysis at Class I filing, supported by data on comparable products. A basic clinical evaluation report therefore remains necessary and cannot be omitted entirely.

Q3: What documents are needed to demonstrate that an equivalence justification is valid?

Equivalence justification must compare the device with the equivalent device across three dimensions: technical (materials, design, mechanical performance), biological (body contact, contact duration, released substances) and clinical (indications, site of use, patient population). The documents required include: evidence of market approval for the equivalent device (such as a CE certificate or FDA 510(k)), a detailed technical parameter table for the equivalent device, biocompatibility test reports (ISO 10993 series), clinical literature (including clinical studies and systematic reviews on the equivalent device), and a detailed equivalence justification report comparing each item and explaining any differences. The equivalent device should have a registration history in the target market and its technical data must be obtainable. If the differences are substantial, a bridging study may be required.

Related Reading

• How to Reuse Medical Device Registration Documentation Across GHWP Member States
• How to Select a Local Agent for Overseas Medical Device Registration
• How to Prepare Labels and Instructions for Overseas Medical Device Registration
• How to Use an ISO 13485 Certificate in Overseas Medical Device Registration
• What Are the Risk Management Documentation Requirements for Overseas Medical Device Registration?
• How to Build a Core Technical File for Multi-Country Medical Device Registration

Content Review and Scope of Application

Author: AIMEILI Regulatory Editorial Team
Professional review: AIMEILI Medical Device International Registration Project Team
Source principle: Priority is given to official regulatory authorities, international organisations, standards bodies and publicly available regulatory materials; industry media and project experience serve only as supporting judgement.
Scope of application: This article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the target country's regulatory authority, test conclusions or legal advice.